Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Implants / Devices
    • J&J faulty hip...

    J&J faulty hip implants: Review for compensation sought

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-01-10T10:00:19+05:30  |  Updated On 10 Jan 2019 10:00 AM IST
    J&J faulty hip implants: Review for compensation sought

    Meanwhile, representatives of the Johnson and Johnson(J&J) also met with the central committee headed by Dr R K Arya during the day.


    New Delhi: Victims of the faulty hip implants made by the Johnson and Johnson subsidiary DePuy International Wednesday met the expert committee formed by the Centre, which has devised the compensation formula for them, for the first time and demanded a review of the plan citing various shortcomings.


    The patients and members of the Hip Implant Patients Support Group (HIPS), who have come here from across the country, also demanded that the compensation is accompanied with prosecution and accountability of Johnson and Johnson.


    Meanwhile, representatives of the Johnson and Johnson also met with the central committee headed by Dr R K Arya during the day.


    The compensation formula which was approved in November last year had drawn ire from the patients and their family members, who asked the Union Health Ministry to involve them in the entire process so that they receive "fair" compensation.


    Read Also: Compensation formula: Delhi HC junks Johnson and Johnson’s plea

    The meeting has come after months of letters and demands by the HIPS that the government meet them and understand the full extent of the damage done by the faulty hip implants.


    Some of the deficiencies, mentioned by the victims, relate to the exclusion of patients such as those who have died, cases of multiple implants and issues related to the non-pecuniary component.


    Vijay Anant Vojhala, an affected patient complained that the current central committee completely ignored the component of medical management of affected patients despite recommendations of a previous expert committee set up last year to look into this issue.


    "Also, we apprised the committee about the patients not being offered life insurances and health insurances," Vojhala said, adding that the entire compensation formula is full with ambiguities.


    Around 40 patients also alleged that the committee only consulted with Johnson and Johnson representatives during the process, while patients were sidelined. They expressed unhappiness over the compensation amount is low as compared to the international standards.


    "Many of our members are in the consumer court or in other forums, demanding justice from J&J and the government. We will continue our efforts on all fronts. We have made it clear to the government and the central expert committee that compensation is only one part of our battle. We will not rest till J&J is investigated, prosecuted and held accountable for their criminal negligence and actions that have left us disabled, in pain and with life long suffering," Vojhala, a resident of Mumbai, added.


    Activist Malini Aisola, who is associated with the HIPS, said: "Several of the patients who had attended the meeting have not applied for compensation because there were concerns about the lack of participation and compensation formula and the process that will be employed."


    Meanwhile, the company issued a statement saying, "Johnson and Johnson Private Limited appreciates the meeting today with the government. We remain committed to providing assistance, including appropriate compensation within an established framework, to ASR patients in India who have undergone revision surgery. We look forward to a positive resolution of this matter."

    Going by the formula approved the health ministry, each patient is likely to receive a compensation amount ranging between Rs 30 lakh and Rs 1.23 crore. The formula was drawn based on the patient's age, level of disability due to the implant, a base compensation of Rs 20 lakh, along with Rs 10 lakh for non-pecuniary damages.


    Read Also: Johnson and Johnson, Health Ministry to meet to Discuss compensation to faulty implant victims


    The pharmaceutical company Johnson and Johnson recalled the faulty metal-on-metal Articular Surface Replacement (ASR) hip implants in 2010 globally after studies red-flagged the high rate of revision surgeries.


    In October last year, the government had constituted the five-member central expert committee to determine the quantum of compensation to be given to the patients who received the "faulty" hip implants.

    articular surface replacementASRcompensationcriminal negligenceDePuy Hip RecallDePuy ProstheticsDr r k aryahealth insuranceHip Implant Patients Support Grouphip implantsHIPSJ&JJohnson and JohnsonNew DelhiUnion Health MinistryVijay Anant Vojhala
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok